SUZHOU, China, and ROCKVILLE, Md., July 19, 2021 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of National Institutes of Health, under which they will collaborate on the non-clinical and clinical development of Ascentage Pharma’s drug compound pelcitoclax.
{iframe}https://www.biospace.com/article/ascentage-pharma-establishes-cooperative-r-and-d-agreement-crada-with-the-national-cancer-institute-for-clinical-development-of-ascentage-pharma-s-drug-compound-pelcitoclax/{/iframe}